Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease

References

• Ljungberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur. Urol.51, 1502–1510 (2007).
   PubMed Web of Science ®Google Scholar
• Ritchie AWS, de Kernion JB. The natural history and clinical features of renal cell carcinoma. Semin. Nephrol.7, 131–139 (1987).
   PubMed Web of Science ®Google Scholar
• Tykkä H, Hjelt L, Oravisto KJ, Turunen M, Tallberg T. Disappearance of lung metastases during immunotherapy in five patients suffering from renal carcinoma. Scand. J. Respir. Dis. Suppl.89, 123–134 (1974).
   PubMedGoogle Scholar
• Berntsen A, Geertsen PF, Svane IM et al. Therapeutic dendritic cell vacciniation of patients with renal cell carcinoma. Eur. Urol.50, 34–43 (2006).
   PubMed Web of Science ®Google Scholar
• Frankenberger B, Regn S, Geiger C et al. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and moncyte-derived dencritic cells. World J. Urol.23, 166–174 (2005).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alpha-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Uemura H, De Valesco MA. Tumor vaccines in renal cell carcinoma. World J. Urol.26, 147–154 (2008).
   PubMed Web of Science ®Google Scholar
• Brossart P, Stuhler G, Flad T et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res.58(4), 732–736 (1998).
   PubMed Web of Science ®Google Scholar
• Flad T, Spengler B, Kalbacher H et al. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res.58(24), 5803–5811 (1998).
   PubMed Web of Science ®Google Scholar
• Neumann E, Engelsberg A, Decker J et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res.58(18), 4090–4095 (1998).
   PubMed Web of Science ®Google Scholar
• Vissers JL, De Vries IJ, Schreurs MW et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res.59(21), 5554–5559 (1998).
   Google Scholar
• Tso CL, Zisman A, Pantuck A et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res.61(21), 7925–7933 (2001).
   PubMed Web of Science ®Google Scholar
• Uemura H, Fujimoto K, Tanaka M et al. A Phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin. Cancer Res.12(6), 1768–1775 (2006).
   PubMed Web of Science ®Google Scholar
• Iiyama T, Udaka K, Takeda S et al. WT1 (Wilms’ tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol. Immunol.51(5), 519–530 (2007).
   PubMed Web of Science ®Google Scholar
• Amato RJ. Vaccine therapy for renal cell carcinoma. Rev. Urol.5(2), 65–71 (2003).
   PubMedGoogle Scholar
• Avigan D. Dendritic cell/tumour fusions vaccine. Dev. Biol. (Basel)116, 161–168 (2004).
   PubMedGoogle Scholar
• Kübler H, Vieweg J. Vaccines in renal cell carcinoma. Semin. Oncol.33, 614–624 (2006).
   PubMed Web of Science ®Google Scholar
• Ranieri E, Gignate M, Storkus WJ, Gesualdo L. Translational mini-review series on vaccines: dendritic cell-based vaccines in renal cancer. Clin. Exp. Immunol.147, 395–400 (2007).
   PubMedGoogle Scholar
• Ernstoff MS, Crocenzi TS, Seigne JD et al. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin. Cancer Res.13, 733–740 (2007).
   Google Scholar
• Van Poppel H, Joniau S, Van Gool S. Vaccine therapy in patients with renal cell carcinoma. Eur. Urol.55, 1333–1344 (2009).
   PubMedGoogle Scholar
• Höltl L, Rieser C, Papesh C et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol.161, 777–782 (1999).
   PubMed Web of Science ®Google Scholar
• Höltl L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res.8, 3369–3376 (2002).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Sunitinib versus interferon α in metastatic renal cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Barbuto JA, Ensina LF, Neves AR et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother.54, 663–670 (2005).
   PubMedGoogle Scholar
• Wierecky J, Müller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res.66, 5910–5918 (2006).
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee Y, Bae YS et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin. Immunol.125(3), 257–267 (2007).
   PubMedGoogle Scholar
• Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J. Immunother.30(1), 116–122 (2007).
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Haraguchi K, Takahashi T et al. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int. J. Urol.14(4), 277–283 (2007).
   PubMedGoogle Scholar
• Avigan DE, Vasir B, George DJ et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother.30(7), 749–761 (2007).
   PubMed Web of Science ®Google Scholar
• Wei YC, Sticca RP, Li J et al. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: a pilot study. Oncol. Rep.18(3), 665–671 (2007).
   PubMedGoogle Scholar
• Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase I study. J. Immunother.25, 500–508 (2002).
   PubMed Web of Science ®Google Scholar
• Soleimani A, Berntsen A, Svanet IM, Pederson AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand. J. Immunol.70(5), 481–489 (2009).
   PubMedGoogle Scholar
• Schwaab T, Schwarzer A, Wolf B et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with aldesleukin (interleukin 2) and IFN-α2a therapy in metastatic renal cell carcinoma patients. Clin. Cancer Res.15(15), 4986–4992 (2009).
   PubMed Web of Science ®Google Scholar
• Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev. Vaccines3, 403–411 (2004).
   PubMedGoogle Scholar
• Guida M, Colluci G. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? Ann. Oncol.18, 149–152 (2007).
   PubMedGoogle Scholar
• Kurth KH, Marquet R, Zwartendijk J, Warnaar SO. Autologous anticancer antigen preparation for specific immunotherapy in advanced renal cell carcinoma. Eur. Urol.13, 103–109 (1987).
   PubMedGoogle Scholar
• McCune CS, Schapira DV, Henshaw EC. Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer47, 1984–1987 (1981).
   PubMed Web of Science ®Google Scholar
• Schärfe T, Müller S, Riedmiller H et al. Jacobi GH, Hohenfellner R. Immunotherapy of metastasizing renal cell carcinoma. Results of a multicentered trial. Urol. Int.44, 1–4 (1989).
   PubMedGoogle Scholar
• Galligioni E, Quaia M, Merlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. Cancer77(12), 2560–2566 (1996).
   PubMed Web of Science ®Google Scholar
• Schwaab T, Heaney JA, Schned AR et al. A randomized Phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J. Urol.163, 1322–1327 (2000).
   PubMed Web of Science ®Google Scholar
• Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet363, 594–599 (2004).
   PubMed Web of Science ®Google Scholar
• Dillman R, Barth N, Vandermolen L et al. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother. Radiopharm.19(5), 570–580 (2004).
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Mescher MF, Okazaki I et al. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am. J. Clin. Oncol.31(2), 173–181 (2008).
   PubMedGoogle Scholar
• Repmann R, Wagner S, Richter A. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor cell lysate vaccine. Anticancer Res.17, 2879–2882 (1997).
   PubMed Web of Science ®Google Scholar
• Doehn C, Richter A, Theodor RA et al. An adjuvant vaccination with Reniale prolongs survival in patients with RCC following radical nephrectomy: secondary analysis of a multicenter Phase-III trial. J. Urol.177(Suppl.), 167 (2007) (Abstract 500).
   Google Scholar
• Doehn C, Esser N, Pauels HG et al. Mode-of-actin, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Eur. Urol.56(1), 123–131 (2009).
   PubMedGoogle Scholar
• May M, Kendel F, Hoschke B et al. Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years. Urologe A48(9), 1075–1083 (2009).
   PubMedGoogle Scholar
• Frankenberger B, Regn S, Geiger C et al. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J. Urol.23(3), 166–174 (2005).
   PubMed Web of Science ®Google Scholar
• Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte–macrophage colony-stimulating factor gene transfer. Cancer Res.57(8), 1537–1546 (1997).
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Seigne J, Diaz J et al. Phase I trial of a B7–1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol.167(5), 1995–2000 (2002).
   PubMed Web of Science ®Google Scholar
• Pizza G, De Vinci C, Lo Conte G et al. Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol. (Praha)50(6), 175–183 (2004).
   PubMed Web of Science ®Google Scholar
• Fishman M, Hunter TB, Soliman H et al. Phase II trial of B7–1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J. Immunother.31(1), 72–80 (2008).
   PubMedGoogle Scholar
• Liao SY, Brewer C, Závada J et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am. J. Pathol.145(3), 598–609 (1994).
   PubMed Web of Science ®Google Scholar
• Saarnio J, Parkkila S, Parkkila AK et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol.153(1), 279–285 (1998).
   PubMed Web of Science ®Google Scholar
• Saarnio J, Parkkila S, Parkkila AK et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J. Histochem. Cytochem.46(4), 497–504 (1998).
   PubMed Web of Science ®Google Scholar
• Turner JR, Odze RD, Crum CP et al. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum. Pathol.28(6), 740–744 (1997).
   PubMed Web of Science ®Google Scholar
• Swinson DE, Jones JL, Richardson D et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J. Clin. Oncol.21(3), 473–482 (2003).
   PubMed Web of Science ®Google Scholar
• Gouttefangeas C, Stenzl A, Stevanović S, Rammensee HG. Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother.56(1), 117–128 (2007).
   PubMed Web of Science ®Google Scholar
• Suekane S, Nishitani M, Noguchi M et al. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci.98(12), 1965–1968 (2007).
   PubMed Web of Science ®Google Scholar
• Patel PM, Sim S, O’Donnell DO et al. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur. J. Cancer44(2), 216–223 (2008).
   PubMed Web of Science ®Google Scholar
• Vieweg J, Jackson A. Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin. Biol. Ther.4(11), 1791–1801 (2004).
   PubMed Web of Science ®Google Scholar
• Elkord E, Shablak A, Stern PL, Hawkins RE. 5T4 as a target for immunotherapy in renal cell carcinoma. Expert Rev. Anticancer Ther.9(12), 1705–1709 (2009).
   PubMed Web of Science ®Google Scholar
• Ward CM, Barrow K, Woods AM, Stern PL. The 5T4 oncofetal antigen is an early differentiation marker of mouse ES cells and its absence is s useful means to assess pluripotency. J. Cell Sci.116, 4533–4542 (2003).
   PubMedGoogle Scholar
• Ward CM, Easthem AM, Stern PL. Cell surface 5T4 antigen is transiently upregulated during early human embryonic stem cell differentiation: effect of 5T4 phenotype on neural lineage formation. Exp. Cell Res.312, 1713–1726 (2006).
   PubMedGoogle Scholar
• Amato RJ, Shingler W, Stuart N et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (Trovax) administered with Interleukin 2: a Phase II trial. Clin. Cancer Res.14(22), 7504–7510 (2008).
   PubMed Web of Science ®Google Scholar
• Kim DW, Krishnamurthy V, Bines SD, Kaufman HL. Trovax, a recombinant modified vaccinia Ankara virus encoding 5T4. Lessons learned and future development. Hum. Vaccin.10, 1–8 (2010).
   Google Scholar
• Hawkins R, Harrop R, Naylor S et al. TRIST: a randomised, double blind, placebo controlled Phase III study of MVA-5T4 in metastatic renal cancer. Presented at: Joint ECCO 15th – 34th ESMO Multidisciplinary Congress. Berlin, Germany, 20–24 September 2009.
   Google Scholar
• Rahma OE, Ashtar E, Ibrahim R et al. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J. Transl. Med.8, 8 (2010).
   PubMedGoogle Scholar
• Brugger W, Zdrojowy R, Pluzanska A et al. Survival update of a randomized Phase 2 study (IMA901–202) investigating therapeutic vaccination with multiple tumor-associated peptides (TUMAP) in renal cell carcinoma (RCC) patients after failure of previous therapy with cytokines or kinase inhibitors. Presented at: 35th ESMO Congress. Milan, Italy, 8–12 October 2010.
   Google Scholar
• Singh H, Hilf N, Mendrzyk R et al. Correlation of immune responses with survival in a randomized Phase II study investigating multi-TUMAP vaccinations with IMA901 plus/minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC). Programs and Abstracts of the American Society of Clinical Oncology. Chicago, IL, USA, 4–8 June 2010 (Abstract 258).
   Google Scholar
• Reinhardt C, Zdrojowy R, Szczylik C et al. Results of a ranomized Phase 2 study investigating multi-peptide vaccination with IMA901 in advanced renall cell carcinoma (RCC). Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 4–8 June 2010.
   Google Scholar
• Wood C, Srivastava P, Bukowski R et al. An adjuvant autologous therapeutic vaccine (HSPCC-96; vitespen) versus observation alone for patients at high-risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised Phase III trial. Lancet372, 145–154 (2008).
   PubMed Web of Science ®Google Scholar
• Jonasch E, Wood C, Tamboli P et al. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br. J. Cancer98, 1336–1341 (2008).
   PubMed Web of Science ®Google Scholar
• Kim HL, Sun X, Subjeck JR, Wang XY. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol. Immunother.56, 1097–1105 (2007).
   PubMed Web of Science ®Google Scholar
• Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer38, 489–494 (1986).
   PubMed Web of Science ®Google Scholar
• Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res.57, 2827–2831 (1997).
   PubMed Web of Science ®Google Scholar
• Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. Anti-renal cell carcinoma chimeric antibody G250. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer. Immunol. Immunother.51, 171–177 (2002).
   PubMed Web of Science ®Google Scholar
• Bevan P, Mala C, Kindler M, Siebels M, Oberneder R, Beck HJ. Results of a Phase I/II study with monoclonal antibody CG250 in combinaton with IFNα-2A in metastatic renal cellcarcinoma patients. J. Clin. Oncol.22(14S), 4606 (2004).
   Google Scholar
• Oosterwijk E, Divgi CR, Brouwers A et al. Monoclonal antibody-based therapy for renal cell carcinoma. Urol. Clin. North Am.30, 623–631 (2003).
   PubMedGoogle Scholar
• Shuch B, Li Z, Belldegrun AS. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. BJU Int.101(Suppl. 4), 25–30 (2008).
   PubMedGoogle Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol.3(11), 991–998 (2002).
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol.24, 1169–1177 (2006).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kuniyasu Y, Toda M et al. Immnologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmne disease by breaking their anergic/suppressive state. Int. Immunol.10, 1969–1980 (1998).
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer. Inst.94(11), 805–818 (2002).
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115, 3623–3633 (2005).
   PubMed Web of Science ®Google Scholar
• Höltl L, Ramoner R, Zelle-Rieser C et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophophamide. Cancer Immunol. Immunother.54, 663–670 (2005).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol.28, 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother.30(8), 825–830 (2007).
   PubMed Web of Science ®Google Scholar
• Graber K. Companies waver in efforts to target transforming growth factor β in cancer. J. Natl Cancer Inst.102, 1664–1667 (2009).
   Google Scholar
• Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochem. Biophys. Acta1776(1), 108–123 (2007).
   PubMedGoogle Scholar
• Hernandez JM, Bui MH, Han KR et al. Novel kidney cancer immunotherapy based in the granulocyte–macrophage colony-stimulating factor and carbonic anhydrase IX. Clin. Cancer Res.9, 1906–1916 (2003).
   PubMed Web of Science ®Google Scholar
• Herbert N, Haferkamp A, Schmitz-Winnenthal, Zöller M. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection. J. Immunol.185(2), 902–916 (2010).
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res.14, 6674–6682 (2008).
   PubMed Web of Science ®Google Scholar
• Hipp MM, Hilf N, Walter S et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood111, 5610–5620 (2008).
   PubMed Web of Science ®Google Scholar
• Krusch M, Salih J, Schlicke M et al. The kinase inhibiitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J. Immunol.183, 8286–8294 (2009).
   PubMedGoogle Scholar
• Seliger B, Massa C, Rini B, Ko J, Finke J. Antitumor and immune-adjuvnat activities of protein-tyrosine kinase inhibitors. Trends Mol. Med.16, 184–192 (2010).
   PubMedGoogle Scholar
• Roigas J. Lecture at the 3. Symposium. Presented at: Clinical and Experimental Research in Renal Cell Carcinoma. Jena, Germany, 29–30 October 2010.
   Google Scholar
• Ablin RJ. Immunotherapy for prostatic cancer. Previous and prospective considerations. Oncology31(3), 177–202 (1975).
   PubMedGoogle Scholar
• Märten A, Flieger D, Renoth S et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/II trial. Cancer Immunol. Immunother.51(11–12), 637–644 (2002).
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res.63(9), 2127–2133 (2003).
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Belldegrun AS, Zisman A et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother.26(5), 412–419 (2003).
   PubMed Web of Science ®Google Scholar
• Märten A, Renoth S, Heinicke T et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther.14(5), 483–494 (2003).
   PubMed Web of Science ®Google Scholar
• Arroyo JC, Gabilondo F, Llorente L et al. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J. Clin. Immunol.24(1), 86–96 (2004).
   PubMed Web of Science ®Google Scholar
• Pandha HS, John RJ, Hutchinson J et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a Phase I/II study. BJU Int.94(3), 412–418 (2004).
   PubMed Web of Science ®Google Scholar
• Wittig B, Märten A, Dorbic T et al. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical Phase I/II trial. Hum. Gene Ther.12(3), 267–278 (2001).
   PubMed Web of Science ®Google Scholar
• Tani K, Azuma M, Nakazaki Y et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol. Ther.10(4), 799–816 (2004).
   PubMed Web of Science ®Google Scholar